Skye Bioscience, Inc.

Operator - CALL INTRODUCTION

Good morning and welcome to Skye and Redx’s definitive Transaction Agreement and Financing Presentation.

Speaking on today's Presentation will be Skye’s Chief Executive Officer, Punit Dhillon and Redx’s Chief Executive Officer, Lisa Anson.

Please note that this conference is being recorded. A copy of the investor presentation accompanying this call is available on the Investor Relations pages of both companies' websites.

Today's discussion will include statements about future expectations, plans and prospects that constitute forward-looking statements within the meaning of the federal securities laws. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including the risk factors discussed in Skye’s SEC filings. You are advised to read, when available, Skye’s filings with the SEC, including a proxy statement to be used in connection with the special meeting of shareholders to approve the transaction because these documents will contain important information about the transaction and the participants' interest in such transaction.

In addition, any forward-looking statements represent management views only as of today, August 14, 2026, and should not be relied upon as representing either company’s views as of any subsequent date. While the companies may elect to update these forward-looking statements at some point in the future, they specifically disclaim any obligation to do so even if their views change, except as required by law.